Zinc supplementation as an adjunct to antibiotics in the treatment of pneumonia in children 2 to 59 months of age by Haider, Batool A. et al.
eCommons@AKU
Woman and Child Health Division of Woman and Child Health
October 2011
Zinc supplementation as an adjunct to antibiotics
in the treatment of pneumonia in children 2 to 59
months of age
Batool A. Haider
Aga Khan University, batool.ali@aku.edu
Zohra S. Lassi
Aga Khan University
Amina Ahmed
Aga Khan University
Zulfiqar Ahmed Bhutta
Aga Khan University, zulfiqar.bhutta@aku.edu
Follow this and additional works at: https://ecommons.aku.edu/
pakistan_fhs_mc_women_childhealth_wc
Part of the Medical Pharmacology Commons, and the Pediatrics Commons
Recommended Citation
Haider, B., Lassi, Z., Ahmed, A., Bhutta, Z. A. (2011). Zinc supplementation as an adjunct to antibiotics in the treatment of
pneumonia in children 2 to 59 months of age. Cochrane Database of Systematic Reviews(10), 7368.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_women_childhealth_wc/88
Cochrane Database of Systematic Reviews
Zinc supplementation as an adjunct to antibiotics in the
treatment of pneumonia in children 2 to 59months of age
(Review)
Haider BA, Lassi ZS, Ahmed A, Bhutta ZA
Haider BA, Lassi ZS, Ahmed A, Bhutta ZA.
Zinc supplementation as an adjunct to antibiotics in the treatment of pneumonia in children 2 to 59 months of age.
Cochrane Database of Systematic Reviews 2011, Issue 10. Art. No.: CD007368.
DOI: 10.1002/14651858.CD007368.pub2.
www.cochranelibrary.com
Zinc supplementation as an adjunct to antibiotics in the treatment of pneumonia in children 2 to 59months of age (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
Figure 4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
Figure 5. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
Figure 6. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
11DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
13REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
15CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
26DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Zinc supplementation versus placebo, Outcome 1 Time-to-clinical recovery. . . . . 26
Analysis 1.2. Comparison 1 Zinc supplementation versus placebo, Outcome 2 Time-to-recovery from tachypnoea
(respiratory rate > 50 breaths per min). . . . . . . . . . . . . . . . . . . . . . . . . . 27
Analysis 1.3. Comparison 1 Zinc supplementation versus placebo, Outcome 3 TIme-to-recovery from chest in-drawing. 28
Analysis 1.4. Comparison 1 Zinc supplementation versus placebo, Outcome 4 Time-to-hospital discharge. . . . . 29
29ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
31APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
34WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
34CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
34DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
34SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
35INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iZinc supplementation as an adjunct to antibiotics in the treatment of pneumonia in children 2 to 59 months of age (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Zinc supplementation as an adjunct to antibiotics in the
treatment of pneumonia in children 2 to 59 months of age
Batool A Haider1, Zohra S Lassi2 , Amina Ahmed3, Zulfiqar A Bhutta2
1Departments of Epidemiology and Nutrition, Harvard School of Public Health, Boston, MA, USA. 2Division of Women and Child
Health, Aga KhanUniversity Hospital, Karachi, Pakistan. 3Department of Paediatrics and ChildHealth, Aga KhanUniversity Hospital,
Karachi, Pakistan
Contact address: Zulfiqar A Bhutta, Division of Women and Child Health, Aga Khan University Hospital, Stadium Road, PO Box
3500, Karachi, 74800, Pakistan. zulfiqar.bhutta@aku.edu.
Editorial group: Cochrane Acute Respiratory Infections Group.
Publication status and date: Edited (no change to conclusions), published in Issue 2, 2013.
Citation: Haider BA, Lassi ZS, Ahmed A, Bhutta ZA. Zinc supplementation as an adjunct to antibiotics in the treatment of
pneumonia in children 2 to 59 months of age. Cochrane Database of Systematic Reviews 2011, Issue 10. Art. No.: CD007368. DOI:
10.1002/14651858.CD007368.pub2.
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Diarrhoeal disorders and acute respiratory infections (ARIs), especially pneumonia, are the most common causes of death in low-
income countries. Studies evaluating the impact of zinc supplementation as an adjunct in the management of pneumonia are limited
and have shown variable results.
Objectives
To evaluate zinc supplementation, as an adjunct to antibiotics, in the treatment (clinical recovery) of pneumonia in children aged two
to 59 months.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2011, Issue 1), which contains the
Cochrane Acute Respiratory Infections (ARI) Group’s and the Cochrane Infectious Diseases Group’s Specialised Registers, MEDLINE
(1950 to March week 2, 2011), EMBASE (1974 to March 2011), CINAHL (1981 to March 2011), LILACS (1985 to March 2011),
AMED (1985 to March 2011), CAB Abstracts (1910 to March 2011) and Web of Science (2000 to March 2011).
Selection criteria
Randomised control trials (RCTs) evaluating supplementation of zinc as an adjunct to antibiotics for pneumonia in children aged two
to 59 months.
Data collection and analysis
Two review authors independently assessed trial eligibility and screened all available titles and abstracts for inclusion. If the relevance
could not be ascertained by screening the title and abstract, we retrieved and reviewed the full text of the article.
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Main results
We included four trials in which 3267 children aged two to 35 months participated. Analysis showed that zinc supplementation in
addition to standard antibiotic therapy in children with severe and non-severe pneumonia failed to show a statistically significant effect
on time-to-clinical recovery (hazard ratio 1.02; 95% confidence interval (CI) 0.93 to 1.11). Similary, zinc supplementation in children
with severe pneumonia, as an adjunct to standard antibiotic therapy, did not show a statistically significant effect on time-to-recovery
from tachypnoea (respiratory rate > 50 breaths per minute) (hazard ratio 1.13; 95% CI 0.82 to 1.57) and time-to-recovery from chest
in-drawing (hazard ratio 1.08; 95% CI 0.88 to 1.31) as compared to the control group. Zinc supplementation in children with severe
pneumonia also showed a non-significant effect on time-to-hospital discharge as compared to the control (hazard ratio 1.04; 95% CI
0.89 to 1.22).
Authors’ conclusions
Evidence provided in this review is insufficient to recommend the use of zinc as an adjunct to standard antibiotic therapy for pneumonia
in children aged two to 35 months.
P L A I N L A N G U A G E S U M M A R Y
Zinc supplementation as an adjunct to antibiotics in the treatment of pneumonia in children two to 59 months of age
Gastroenteritis and respiratory infections (particularly pneumonia) are the two most common causes of death in low-income countries.
Preventive zinc supplementation may correct any deficiency leading to immunodeficiency and indeed some evidence suggests that
preventive zinc supplementationmay reduce childmortality andmorbidity from infectious diseases, particularly pneumonia. Pnumeonia
is the inflammation of the lungs and is caused by viruses, bacteria or other microorganisms. Studies evaluating the impact of zinc
supplementation as an adjunct in the management of pneumonia are limited and have shown variable results. The aim of this review is
to evaluate the role of zinc supplementation, as an adjunct to antibiotics, in the treatment of pneumonia in children aged two months
to 59 months.
The review authors found four randomised control trials of adequate quality evaluating the impact of zinc supplementation as an
adjunct to antibiotics for pneumonia in children. These studies were conducted in Bangladesh, Nepal and India, in which 3267 children
aged two to 35 months were randomly assigned to receive zinc or placebo. No serious adverse events were observed. Analysis did not
show any significant effect on the clinical recovery of patients in terms of time-to-recovery from tachypnoea (respiratory rate > 50
breaths per minute) and time-to-recovery from chest indrawing. It also showed non-significant effects of the intervention on the time-
to-hospital discharge. Evidence provided in this review is insufficient to recommend use of zinc as an adjunct to standard antibiotic
therapy for pneumonia in children aged two to 35 months.
B A C K G R O U N D
Description of the condition
Acute respiratory infections (ARIs), especially pneumonia and di-
arrhoeal disorders are the two most common causes of death in
low-income countries (Bryce 2005; Rudan 2008). The annual
estimated incidence of pneumonia is 151 million new cases per
year (Rudan 2004), of which two million die annually. It is the
largest killer, accounting for 19% of all child deaths in low-income
countries (Bryce 2005; Rudan 2008), and with the inclusion of
neonatal pneumonia, recent estimates indicate that it accounts for
28% to 34% of deaths globally in children below five years of
age (Wardlaw 2006). Interventions that affect mortality due to
pneumonia are thus of great importance in any effort to improve
childhood survival.
Description of the intervention
Zinc is a trace element and an essential mineral which is present in
all tissues, fluids and secretions in the body. It is critical to cellular
metabolism, physical growth, immunocompetence, reproductive
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functions, integrity of intestinal mucosa and neuro-behavioural
development (Aggett 1995; Bhatangar 2004). Zinc deficiency
is associated with decreased immunocompetence (Golden 1995;
Sazawal 1997; Shankar 1998), high rates of serious infectious
disease, such as skin infections, diarrhoea, respiratory infections,
malaria (Black 2001; Lopez 1989; Murray 1996) and delayed
wound healing (Bahl 1998; Black 1998; Prasad 1985). Zinc defi-
ciency may be an underlying cause of increased infant mortality in
malnourished children in low-income countries (Castillo-Duran
2001).
The daily requirement of zinc varies with age, with the recom-
mended dietary allowance (RDA) for infants and children aged
one to five years being 5 mg and 10 mg per day, respectively
(RDA 1989). Manifestations of zinc deficiency also vary with age
(Hambidge 1986). Diarrhoea, neuro-behavioural problems and
learning impairment are prominent symptoms of zinc deficiency
in infancy (Penland 2000) and skin problems, hair loss, growth re-
tardation and recurrent infections are common findings in school-
aged children (Van Wouwe 1989). Zinc deficiency has at least five
general causes: inadequate intake from foods (particularly from
animal sources), increased requirements, malabsorption, increased
losses during recurrent diarrhoeal illnesses (Bhutta 1999; Black
1998) and impaired metabolic utilisation (Solomons 1984).
How the intervention might work
Zinc plays an important role in maintaining a normal immune
function and participates in all major biochemical pathways.
It plays multiple roles in the perpetuation of genetic mate-
rial and cellular division. Studies have suggested that zinc defi-
ciency impairs immunocompetence with reduced cell-mediated
immune responses, decreased T-lymphocytes, abnormal T-helper
and/or suppressor functions, impaired macrophage function, re-
duced killer cells and antibody dependent cytotoxicity (Ibs 2003;
Ravaglia 2000). Zinc supplementation in children causes an in-
crease in the levels of complement in the blood that modulate
the function of monocytes, macrophages and neutrophils poly-
morphs. It also helps in the development and activation of T-lym-
phocytes. When zinc supplements are given to individuals with
low levels of zinc, the numbers of T-cell lymphocytes circulating in
the blood increase and the ability of lymphocytes to fight against
infection improves (Fraker 1993). Preventive zinc supplementa-
tion may correct any deficiency leading to immunodeficiency and
indeed some evidence suggests that preventive zinc supplementa-
tionmay reduce childmortality andmorbidity from infectious dis-
eases, particularly diarrhoea and pneumonia (Bhutta 1999; Lassi
2010). Zinc supplementation during respiratory infections could
work through similar pathways to reduce morbidity and expedite
recovery. Because zinc is not stored in the body, adequate zinc
supplementation is required.
Why it is important to do this review
Current evidence on zinc supplementation as a preventative mea-
sure has shown beneficial effects by reducing the incidence of diar-
rhoea and pneumonia in children (Aggarwal 2007; Bhutta 1999;
Bhutta 2008; Brooks 2005). The preventative aspect of zinc in
reducing pneumonia has also been evaluated in another Cochrane
review (Lassi 2010). Established evidence of the benefit of zinc
supplementation in the management of children with diarrhoea,
along with oral rehydration solution, is available and has formed
the basis of the Joint WHO/UNICEF recommendation (WHO
2004). Studies evaluating the impact of zinc supplementation as
an adjunct in the management of pneumonia are limited and have
shown variable results. The Brooks 2004 trial shows a reduction in
the duration of pneumonia in young children when zinc is admin-
istered along with an antimicrobial therapy. However, the Bose
2006 trial failed to show a benefit of zinc supplementation in the
management of pneumonia. To reduce deaths due to pneumonia,
it is important to evaluate the role of zinc supplementation as an
adjunct to antibiotics, in the treatment of pneumonia in children
aged two months to 59 months.
O B J E C T I V E S
To evaluate the role of zinc supplementation, as an adjunct to
antibiotics, in the treatment (clinical recovery) of pneumonia in
children aged two months to 59 months.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs), irrespective of
publication status and language, evaluating supplementation of
zinc as an adjunct to antibiotics for pneumonia in children aged
two months to 59 months. We included both individual and clus-
ter-RCTs. We excluded non-RCTs (quasi-RCTs).
Types of participants
We included children aged two months to 59 months suffering
frompneumonia.We considered studies of children suffering from
an episode of pneumonia and diagnosed in the following ways.
1. Reported cough or difficulty breathing with a respiratory
rate above the WHO defined age-specific values (respiratory rate
>
= 50 breaths per minute for children aged two to 11 months, or
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respiratory rate
>
= 40 breaths per minute for children aged 12 to
59 months) (WHO 1990); and either documented fever of >
101oF or chest indrawing.
2. A diagnosis of pneumonia based on chest examination by a
physician.
3. A diagnosis of pneumonia based on a chest radiograph.
We excluded studies including children suffering from other de-
bilitating diseases.
Types of interventions
Oral supplements containing zinc versus oral supplements with-
out zinc or a placebo. All participants should receive standard an-
tibiotic therapy. Supplementation of zinc should be the only dif-
ference between the intervention and control group.
Types of outcome measures
Primary outcomes
Time-to-clinical recovery* (clinical recovery defined as recovery
from tachypnoea, fever and chest indrawing for at least 12 to 24
hours).
*Clinical recovery as a composite outcome i.e. resolution of all
three symptoms. We also analysed data for the resolution of indi-
vidual symptoms.
Secondary outcomes
1. Time-to-hospital discharge (from randomisation to
discharge).
2. Re-admission/re-diagnosis with pneumonia within three
months, starting from the last day of current episode.
3. Mortality within 10 days of randomisation.
4. Mortality within one month of randomisation.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled
Trials (CENTRAL) (The Cochrane Library 2011, Issue 1)
www.thecochranelibrary.com (accessed 24 March 2011), which
contains theCochrane Acute Respiratory Infections (ARI)Group’s
and the Cochrane Infectious Diseases Group’s Specialised Regis-
ters, MEDLINE (1950 toMarch week 2, 2011), EMBASE (1974
toMarch 2011), CINAHL (1981 toMarch 2011), LILACS (1985
to March 2011), AMED (1985 to March 2011), CAB abstracts
(1910 toMarch 2011) andWeb of Science (2000 toMarch 2011).
See Appendix 1 for the MEDLINE search strategy. We did not
use a filter to identify randomised trials as there were too few
results. We adapted the search strategy to search CENTRAL (see
Appendix 2), EMBASE (seeAppendix 3),CINAHL(seeAppendix
4), LILACS (see Appendix 5), AMED (see Appendix 6), CAB
abstracts (see Appendix 7) and Web of Science (see Appendix 8).
Searching other resources
We imposed no language or publication restrictions. We also
searched the related conference proceedings for relevant abstracts.
We contacted organisations, researchers in the field and pharma-
ceutical companies for information on unpublished and ongoing
trials. We also checked the reference lists of all trials identified by
the above methods.
Data collection and analysis
Selection of studies
Two review authors (BAH, ZSL) independently assessed trial eli-
gibility and screened all available titles and abstracts for inclusion.
We retrieved and reviewed the full text of the article if we could
not ascertain the relevance of the article by screening the title and
abstract. We independently assessed the eligibility by filling out
eligibility forms designed in accordance with the specified inclu-
sion criteria. We resolved any disagreements by discussion or, if
required, we consulted a third review author (ZAB). We displayed
studies excluded from the review in theCharacteristics of excluded
studies table along with the reason(s) for exclusion.
Data extraction and management
Two review authors (BAH, ZSL) piloted, tested and subsequently
used a data extraction form to collect data. Both review authors
then compared the extracted data to enable them to correct errors
and resolve any disagreements through discussion. We used the
Review Manager (RevMan) software (RevMan 2011) for data en-
try.
We attempted to contact the trial authors to provide further details
when information regarding any of the above was unclear.
Assessment of risk of bias in included studies
Two review authors (BAH, ZSL) independently assessed the
methodological quality of the selected trials by using methodolog-
ical quality assessment forms. We undertook quality assessment of
the trials using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). Any disagree-
ments between the two review authors were resolved by discussion.
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1. Sequence generation (selection bias)
For each included studywe described themethods used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups. We assessed the
method as:
• low risk of bias (any truly random process, for example,
random number table, computer random number generator);
• high risk of bias (any non-random process, for example,
odd or even date of birth, hospital or clinic record number); or
• unclear risk of bias.
2. Allocation concealment (selection bias)
For each included study we described themethods used to conceal
the allocation sequence in sufficient detail anddeterminedwhether
intervention allocation could have been foreseen in advance of, or
during recruitment, or changed after assignment. We assessed the
methods as:
• low risk of bias (for example, telephone or central
randomisation, consecutively numbered sealed opaque
envelopes);
• high risk of bias (open random allocation, for example,
unsealed or non-opaque envelopes, alternation, date of birth); or
• unclear risk of bias.
3. Blinding (performance bias)
For each included study we described the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. Studies were judged at low risk
of bias if theywere blinded, or if we judged that the lack of blinding
could not have affected the results. Blindingwas assessed separately
for different outcomes or classes of outcomes. We assessed the
methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel; and
• low, high or unclear risk of bias for outcome assessors.
4. Incomplete outcome data (attrition bias through
withdrawals, dropouts, protocol deviations)
For each included study, and for each outcome or class of out-
comes, we described the completeness of data including attrition
and exclusions from the analysis. We stated whether attrition and
exclusions were reported, the numbers included in the analysis at
each stage (compared with the total randomised participants), rea-
sons for attrition or exclusion where reported, and whether miss-
ing data were balanced across groups or were related to outcomes.
Where sufficient information was reported, or could be supplied
by the trial authors, we re-included missing data in the analyses
which we undertook. We assessed methods as:
• low risk of bias;
• high risk of bias; or
• unclear risk of bias.
5. Free of selective reporting bias
We described for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it is clear that all of the study’s
prespecified outcomes and all expected outcomes of interest to
the review have been reported); or
• high risk of bias (where not all the study’s prespecified
outcomes have been reported; one or more reported primary
outcomes were not prespecified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported); or
• unclear risk of bias.
6. Free of other sources of bias
For each included study we described any important concerns we
had about other possible sources of bias. We assessed whether each
study had:
• low risk of bias;
• high risk of bias; or
• unclear risk of bias.
7. Overall risk of bias
Wemade explicit judgements aboutwhether studies are at high risk
of bias, according to the criteria given in theCochraneHandbook for
Systematic Reviews of Interventions (Higgins 2011). With reference
to (1) to (6) above, we assessed the likely magnitude and direction
of the bias and whether we considered it likely to impact on the
findings. We also explored the impact of the level of bias through
undertaking sensitivity analyses.
Measures of treatment effect
For time-to-event data, we presented results as summary hazard
ratios (HR) with 95% confidence intervals (CIs) such that a HR
>1 reflected faster recovery times in the treatment group as com-
pared to the control group. None of the included studies presented
data for dichotomous outcomes of re-admission/re-diagnosis with
pneumonia and mortality outcomes. However, for future updates,
for these listed outcomes, we will present results as summary risk
ratios (RR) with 95% CIs. We did not include any continuous
outcome in the review.
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Unit of analysis issues
All included studies were individual randomised trials with no
issues of unit of analysis.
Dealing with missing data
For all outcomes, we carried out analyses, as far as possible, on
an intention-to-treat (ITT) basis, i.e. we attempted to include all
participants randomised to each group in the analyses and all par-
ticipants were analysed in the group to which they were allocated,
regardless of whether or not they received the allocated interven-
tion. The denominator for each outcome in each trial was the
number randomised minus any participants whose outcomes are
known to be missing
Assessment of heterogeneity
We measured heterogeneity among trials by calculating the I²
statistic, Chi² statistics and by visual inspection of the forest plots.
If I² statistic exceeded 50%, Chi² P value is less than 0.1, and
visual inspection of the forest plots is indicative, we considered
heterogeneity to be substantial. We did not find substantial het-
erogeneity in any of the outcomes; therefore, did not undertake
any subgroup analyses. However, we evaluated the effect of inter-
vention in subgroups defined on the basis of the severity of disease.
Assessment of reporting biases
For outcomes with 10 or more studies in the meta-analysis, we
planned to investigate reporting biases (such as publication bias)
by using funnel plots. We proposed assessment by evaluating fun-
nel plot asymmetry visually and formal tests for funnel plot asym-
metry; test by Egger 1997 for continuous outcomes and the test
by Harbord 2006 for dichotomous outcomes measuring effects as
odds ratios. However, we did not evaluate for these biases due to
the small number of studies included in the review.
Data synthesis
We carried out statistical analysis using the Review Manager soft-
ware (RevMan 2011). In the absence of significant heterogeneity,
where trials were sufficiently similar, we used a fixed-effect meta-
analysis model for combining data. If we found heterogeneity, we
explored this by a subgroup analyses followed by a random-effects
model, if required.
Subgroup analysis and investigation of heterogeneity
We planned to carry out following subgroup analyses for the in-
vestigation of heterogeneity.
• Different doses of zinc used.
• Different durations of zinc supplementation.
• Baseline zinc deficiency in the population.
• Severity of disease (defined by the presence of either chest
in-drawing or at least one other critical sign, such as central
cyanosis, excessive sleepiness, inability to drink, convulsions).
• Wheezing at the time of enrolment.
• Co-interventions.
Sensitivity analysis
We planned to carry out sensitivity analysis to explore the effect
of trial quality by excluding high risk trials in which method of
randomisation and allocation concealment or blinding was not
achieved or trials with a large loss to follow up (> 20%). However,
we did not do a sensitivity analysis as only Bansal 2011, which did
not contribute any data to the analyses, had inadequate allocation
concealment.
R E S U L T S
Description of studies
Results of the search
We retrieved 381 records from electronic searches up to March
2011. We only retrieved 12 records for full text appraisal and four
met our eligibility criteria.
Included studies
We included four trials in this review with a total of 3267 partic-
ipants.
The Brooks 2004 RCT included 270 children aged between two
and 23 months, diagnosed with severe pneumonia. The trial was
conducted in a rural hospital in Bangladesh. Children with con-
current diarrhoea or severe malnutrition were excluded. The par-
ticipants were randomised to receive 20 mg elemental zinc per day
(10 mg zinc acetate per 5 mL syrup) or placebo until they were
discharged from the hospital. Both groups were similar at baseline
in terms of demographic and social characteristics and baseline
serum zinc levels. The mean serum zinc level at baseline in both
groups was 10.1 µmol/L. The intervention group had a reduced
duration of severe pneumonia and overall length of hospital stay.
The Bose 2006 study conducted in a large referral hospital in
Vellore, India was a randomised trial of 300 children aged be-
tween two and 23 months with severe pneumonia. The children
were randomised to receive either 20 mg of zinc sulphate daily
or placebo until discharge or a maximum of 15 days (whichever
came first). Both groups were similar in demographic and social
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characteristics. The baseline mean serum zinc levels in the inter-
vention and placebo groups were 11.0 µmol/L and 10.9 µmol/
L, respectively. There were no clinically or statistically significant
differences in the duration of tachypnoea, hypoxia, chest indraw-
ing, inability to feed, lethargy, severe illness or hospitalisations.
Zinc supplementation was associated with a significantly longer
duration of pneumonia in the hot season (summer).
Another study was conducted in Bhaktapur, Nepal in children
aged two to 35 months with cough or difficulty in breathing
(Valentiner-Branth 2010). Children with severe or non-severe
pneumonia (according to the WHO definition) were randomised
to either zinc (10 mg for children aged between two and 11
months, 20 mg for children aged 12 months) or placebo daily for
14 days. There was no difference in time to recovery between the
zinc and placebo groups for non-severe or severe pneumonia.
Bansal 2011 was a prospective, randomised, triple-blind, placebo-
controlled trial, which included children aged two to 24 months,
presenting in the paediatric emergency department of a teaching
referral hospital in north India with severe LRTI (according to the
WHO definition). These children were randomised to either zinc
or a placebo group. The zinc group received 20 mg of elemental
zinc per day (5 ml syrup per day) as a single daily dose after meals
for five days. Zinc supplementation failed to reduce recovery time
and duration of hospital stay in children with acute LRTI.
The outcome of clinical recovery was defined differently in the
above included studies. See Characteristics of included studies
Table 1 and Table 2 for detailed descriptions of study participants,
interventions, outcome definitions and median recovery times.
There are four ongoing trials; the details of methods, participants,
interventions and outcomes are available in the Characteristics of
ongoing studies table.
Excluded studies
Five studies (Chang 2006; Khaled 2001; Mahalanabis 2002;
Mahalanabis 2004; Shah 2011) were excluded as they did not sat-
isfy the inclusion criteria of the review. The studies byMahalanabis
2002 and Chang 2006 included participants up to 15 years of age
and 11 years respectively, and did not report separate outcomes for
children under five years of age. In addition, Mahalanabis 2002
evaluated the effect of zinc on measles-related pneumonia and all
participants received vitamin A in addition to standard antimicro-
bial therapy. The trial conducted by Khaled 2001 was published
only as an abstract and contained insufficient information. The
study by Mahalanabis 2004 in India was a factorial design with
vitamin A. The trial reported only sex-based estimates and was
therefore excluded. The trial by Shah 2011 included children be-
tween six to 59 months of age who were assigned to the zinc or
placebo group and the incidence of acute LRTIs was measured.
Risk of bias in included studies
Figure 1 and Figure 2 provide a graphical summary of the results
of risk of bias for the four included studies.
Figure 1. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
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Figure 2. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
Allocation
The Bose 2006 and Valentiner-Branth 2010 trials had adequate
sequence generation with adequate allocation concealment. How-
ever, Bansal 2011 used a random number table for sequence gener-
ation but allocation concealment was known to the hospital phar-
macist who dispensed the drugs in identical looking serially num-
bered plastic bottles. The Brooks 2004 study does not clearly state
any method for allocation concealment.
Blinding
Participants, study personnel and outcome assessors were blinded
in two trials (Bose 2006; Valentiner-Branth 2010). Participants
were blinded in Brooks 2004 but the blinding of study personnel
and outcome assessors is unclear from the text. Details on blinding
were not given in Bansal 2011. However, they did mention that
the study was a triple-blind study.
Incomplete outcome data
Attritions and exclusions were 1.1%, 1.3%, 1.8% and 2.6% in
Valentiner-Branth 2010, Bose 2006, Bansal 2011 and Brooks
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2004, respectively.
Selective reporting
All outcomes in the included studies have been measured and
reported as predefined in the methodology of the study.
Other potential sources of bias
All included studies appears to be free of other sources of bias.
Effects of interventions
Primary outcome measure
Zinc supplementation in addition to standard antibiotic therapy
in children with severe and non-severe pneumonia did not show
any statistically significant effect on time-to-clinical recovery as
compared to the control (hazard ratio 1.02; 95% CI 0.93 to 1.11,
fixed-effect model (two studies, N = 2862)) (Analysis 1.1; Figure
3). Overall results were not heterogenous (I² = 56%, P value =
0.10). Zinc supplementation as an adjunct to standard antibiotic
therapy failed to show a statistically significant effect on the out-
come among children with severe pneumonia (hazard ratio 1.12;
95% CI 0.89 to 1.41, fixed-effect model (two studies, N = 408))
(Analysis 1.1; Figure 3) and non-severe pneumonia (hazard ratio
1.00; 95% CI 0.91 to 1.10 (one study, N = 2454)) (Analysis 1.1;
Figure 3).
Figure 3. Forest plot of comparison: 1 Zinc supplementation versus placebo, outcome: 1.1 Time-to-clinical
recovery.
In children with severe pneumonia, zinc supplementation as an
adjunct to standard antibiotic therapy failed to show a statistically
significant effect on time-to-recovery from tachypnoea (respiratory
rate > 50 breaths per minute) as compared to the control group
(hazard ratio 1.13; 95% CI 0.82 to 1.57, random-effect model
(two studies, N = 562)) (Analysis 1.2; Figure 4).Overall, the results
were heterogeneous (I² statistic = 69%, P value = 0.07). The effect
of adjuvant zinc supplementation on time-to-recovery from chest
indrawing was not statistically significant as compared to control
(hazard ratio 1.08; 95% CI 0.88 to 1.31, fixed-effect (two studies,
N = 562)) (I² = 57%, P value = 0.13). (Analysis 1.3; Figure 5).
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Figure 4. Forest plot of comparison: 1 Zinc supplementation versus placebo, outcome: 1.2 Time-to-
recovery from tachypnoea (respiratory rate > 50 breaths per min).
Figure 5. Forest plot of comparison: 1 Zinc supplementation versus placebo, outcome: 1.3 TIme-to-
recovery from chest in-drawing.
Results fromBansal 2011were reported only asmedian (interquar-
tile ranges (IQR)) and could not be pooled with the other trials.
The trial displayed no effect of zinc as an adjunct to antibiotic on
the time to clinical recovery (zinc group, median 60 h; IQR: 24
to 78 versus control, median 54 h; IQR: 30 to 72 h, P value =
0.98); resolution of tachypnoea (zinc group, median 60 h; IQR:
24 to 72 versus control, median 48 h; IQR: 24 to 72 h, P value =
0.89); and respiratory distress (zinc group, median 30.5 h; IQR:
16 to 48 versus control, median 24 h; IQR: 13 to 48 h, P value =
0.57).
Secondary outcome measure
Zinc supplementation in children with severe pneumonia showed
a non-significant effect on time-to- hospital discharge as compared
to the control group (hazard ratio 1.04; 95% CI 0.89 to 1.22,
fixed-effect (three studies, N = 707) I² statistic = 56%, P value =
0.1 (Analysis 1.4; Figure 6). The duration of hospital stay in Bansal
2011 was shorter by nine hours in the zinc group. However, the
difference was not significant (P value = 0.53) (zinc group: median
5 days; IQR: 4 to 5.5 versus control: median 5 days; IQR: 3 to
6.5).
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Figure 6. Forest plot of comparison: 1 Zinc supplementation versus placebo, outcome: 1.4 Time-to-hospital
discharge.
The included studies did not measure any effect on the outcomes
of readmission/rediagnosis with pneumonia within three months,
mortality within 10 days of randomisation and mortality within
one month of randomisation. We did not perform any subgroup
analyses because of the small number of studies included in the
review.
D I S C U S S I O N
Summary of main results
Zinc supplementation as an adjunct to antibiotics failed to show
any significant effect on time-to-clinical recovery frompneumonia
in children.We found four trials which compared the effect of zinc
supplementation in children (two to 35months of age) with severe
pneumonia. Data from five trials could not be used in the analy-
sis (Chang 2006; Khaled 2001; Mahalanabis 2002; Mahalanabis
2004; Shah 2011). Three studies included children up to 15
years of age, one reported sex-based estimates and the other was
a published abstract with insufficient information (Chang 2006;
Mahalanabis 2002; Mahalanabis 2004). Another trial compared
zinc versus no zinc and prescribed antibiotics only when pneumo-
nia developed (Shah 2011), whereas Khaled 2001 had insufficient
information and the outcomes reported by the trial were not of
interest to the review.
Brooks 2004 evaluated the effect of 20 mg of daily zinc supple-
mentation on clinical recovery in children treated for severe pneu-
monia with intravenous antibiotic therapy (ampicillin and gen-
tamicin). They did not find any impact of zinc on recovery from
severe pneumonia. The Bose 2006 trial also evaluated the effect of
daily 20 mg zinc supplementation in children with severe pneu-
monia treated with intravenous benzyl penicillin and gentamicin
and found no overall effect of zinc supplementation on clinical
recovery or duration of hospitalisation. Similarly, Bansal 2011 did
not find any significant effect of zinc on clinical recovery and dura-
tion of hospital stay in children presenting with severe LRTI. The
trial from Nepal by Valentiner-Branth 2010 evaluated 10 mg of
zinc for children less than 12 months of age and 20 mg of zinc for
children older than 12 months of age with severe and non-severe
pneumonia. Children with non-severe pneumonia were given oral
cotrimoxazole whereas those with severe pneumonia were treated
with intravenous benzyl/penicillin. Analysis of data from the in-
cluded studies did not show a significant impact of the interven-
tion on time-to-hospital discharge and time-to-clinical recovery
in terms of resolution of tachypnoea and chest indrawing.
Baseline serum zinc levels in children with pneumonia were mea-
sured at the time of recruitment in trials. Since serum zinc lev-
els fall during an acute infection, the baseline values noted at
the time of recruitment may not reflect the true underlying zinc
status (in the absence of an acute infection) of these study pop-
ulations. Differences in the prevalence of zinc deficiency in the
study populations may have implications on the role of adjuvant
zinc therapy in the treatment of pneumonia. Additionally, Bose
2006 and Valentiner-Branth 2010 used benzyl penicillin which
is effective against Streptococcus pneumoniae (S. pneumoniae) but
is not effective against Haemophilus influenzae (H. influenzae).
Both trials used third-generation cephalosporins as second-line
drugs if the patients failed to respond to the first-line treatment.
Cephalosporins have high efficacy which may have lead to similar
recovery rates in the groups masking any potential benefit of zinc
in these patients.
Overall completeness and applicability of
evidence
The four included studies were conducted in Bangladesh, Nepal
and India and the study participants were recruited from hospi-
tals in these low-income countries. Children included two to 35
months old and admitted with severe pneumonia (Bansal 2011;
Bose 2006; Brooks 2004; Valentiner-Branth 2010) and non-se-
vere pneumonia (Valentiner-Branth 2010). Pneumonia was de-
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fined clinically in all studies using more or less similar criteria.
Though baseline zinc levels in children suffering from pneumonia
were measured, prevalences of zinc deficiency in the study popula-
tions were not available. Considering these findings, the results of
the review can be applied to similar populations as those included
in the studies.
Quality of the evidence
Comparability of study methodology and outcome assessment are
of prime importance in compiling evidence. Of note, almost all
trials included in the analysis reported pneumonia to the closest
possible WHO definition. Therefore, there is little risk of bias due
to selective reporting in these trials. Adequate allocation conceal-
ment can avoid selection bias in controlled trials and there is evi-
dence that inadequate allocation concealment leads to an overes-
timation of the treatment effect. In our included trials, allocation
concealment and sequence generation were adequately described
in all except Brooks 2004 and Bansal 2011, which suggests that
results should be interpreted with caution. However, all included
studies were adequately blinded for treatment assignment. Com-
pletion rates were greater than 95%.
Potential biases in the review process
In this review we used clearly specified inclusion and exclusion
criteria and a systematic, comprehensive search strategy for the
identification of relevant studies. Two review authors (BAH, ZSL)
independently undertook study selection and data extraction and
in case of any discrepancy, they reached consensus by discussion
with the third review author (ZAB). We published a protocol for
this review with methods specified a priori.
Agreements and disagreements with other
studies or reviews
We drew consistent findings with previous reviews that also stud-
ied the role of adjuvant zinc therapy in children with pneumonia
(Haider 2009; Natchu 2008). Haider 2009 did not find a bene-
ficial effect of adjunct zinc therapy in children with pneumonia.
However, significant reductions were observed in the mean dura-
tion of acute diarrhoea and persistent diarrhoea in the zinc supple-
mented group compared to the control group. Natchu 2008 con-
cluded that the benefit from zinc supplementation during acute
LRTI is not universal and explained that the variations in the re-
sults were due to the difference in aetiologies, definitions of pneu-
monia and recovery, and the timing of zinc supplementation in
the course of the illness.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review does not provide any evidence for the beneficial effect
of zinc supplementation as an adjunct in the treatment of children
with pneumonia. Results from four ongoing trials will be available
in the near future and contribute to the evidence base for this
intervention.
Implications for research
Well-designed, large scale RCTs are needed to evaluate the effect
of zinc supplementation in the treatment of pneumonia in low-
income countries where zinc deficiency and pneumonia are com-
mon. Future studies may consider evaluating the underlying zinc
deficient status of the populations in a sample of non-diseased
children.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bansal 2011
Methods This prospective, randomised, triple-blind, placebo-controlled trial was conducted from
April 2007 to June 2008 in a teaching referral hospital in north India
Participants Children in the age group of 2 to 24 months presenting to a paediatric emergency
department with severe acute LRTI were eligible for enrolment. Acute LRTI was defined
as presence of tachypnoea (respiratory rate more than 50 breaths per min for children
aged 2 to 12 months and more than 40 breaths per min for children aged > 12 months)
and either chest indrawing (any subcostal recession) or one of the following danger signs:
cyanosis, inability to feed/drink, lethargy and convulsions. Children with concurrent
diarrhoea, severemalnutrition (weight for age < 50% of reference value), congenital heart
disease and those already on zinc supplements were excluded
Interventions Eligible children were randomly allocated to zinc or control groups. Zinc group received
20 mg of elemental zinc per day (5 ml syrup per day) as a single daily dose after meals
for 5 days. Control group received an equal amount of placebo which was appropriately
modified to give the taste, smell, colour and consistency similar to zinc mixture
Outcomes Time to be asymptomatic, time to disappearance of danger signs, time to resolution of
respiratory distress, time to resolution of tachypnoea, duration of stay (days)
Notes The study protocol was approved by Research and Ethics Committees of the hospital and
written informed consent was obtained from parents before enrolment of the subjects
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Simple randomisation sequence
was generated using a random number ta-
ble”
Comment: probably done
Allocation concealment (selection bias) High risk Quote: “Allocation sequence was known
only to hospital pharmacist who dispensed
the study
drugs in identical looking, serially num-
bered, sealed 30 ml plastic bottles”
Comment: probably not done
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Quote: “A Triple-Blind Random-
ized Placebo Controlled Trial”; “Allocation
sequence was known only to hospital phar-
macist who dispensed the study drugs in
identical looking, serially numbered, sealed
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Bansal 2011 (Continued)
30 ml plastic bottles”
Comment: did not mention if participants
and outcome analyser was blinded, while
dispenser was not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 52/53 and 52/53 completed the study
Selective reporting (reporting bias) Low risk Study appears to be free of selective report-
ing
Other bias Low risk The study appears to be free of other
sources of bias
Bose 2006
Methods A randomised, double-blinded, placebo controlled clinical trial conducted in a tertiary
referral hospital in India for a duration of 1 year (September 2003 to August 2004)
to evaluate the effect of adjuvant zinc therapy on recovery from severe pneumonia in
hospitalised children receiving standard antibiotic therapy
Participants Children aged between 2 and 23 months of age who consented to enrol in the study
and were clinically diagnosed by a study physician as having severe pneumonia (having
RR > 50/min accompanied by crepitations on auscultation and presence of at least one
or more of the following danger signs: chest indrawing, lethargy, inability to feed or
central cyanosis) were included. Participants were excluded if they had chronic cardiac or
renal disease, illness severe enough to require ventilation, severe malnutrition requiring
immediate rehabilitation therapy, hospitalisation in the previous 21 days or current zinc
supplementation. 300 participants were enrolled, with 150 participants in each group.
The participant population lived in economically poor conditions and possibly suffered
from malnutrition
Interventions 20 mg of elemental zinc, in the form of zinc sulphate tablets, was administered orally to
the participants in two divided doses. Zinc or placebo were given daily until discharge
from the hospital. Tablets were dissolved in water for younger infants
Outcomes Reported outcomes were: time taken for resolution of severe pneumonia, duration of
hospital stay, time taken for resolution of clinical symptoms as tachypnoea (RR > 50/
min), chest indrawing, inability to feed orally, hypoxaemia (arterial oxygen saturation <
93%), fever (axillary temperature > 37.5 °C) and cough
Notes Children were treated parenterally with a combination of benzyl penicillin and gentam-
icin
Risk of bias
Bias Authors’ judgement Support for judgement
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Bose 2006 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “Randomisation was conducted at
the individual level and in blocks of 8 and
10.” “randomly assigned to each of the
treatment groups”
Comment: probably done
Allocation concealment (selection bias) Low risk Quote: “codes were generated by a scientist
at the headquarters of WHO, which was
not associated with the study.” “Treatment
codes were kept in an envelope in a locked
cabinet at WHO headquarters in Geneva”
Comment: probably done
Blinding (performance bias and detection
bias)
All outcomes
Low risk “double-blind”. “The zinc and placebo
tablets were indistinguishable in appear-
ance, consistency, and taste.” “locked cab-
inets that could be accessed only by study
physicians who were responsible for dosing
the participants”
Comment: blinding of participants, study
personnel and outcome assessors probably
done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Exclusions and attritionwas 1.3%. Reasons
for attrition and exclusions for all major
outcomes in each intervention group were
reported
Selective reporting (reporting bias) Low risk All outcomes have been measured and re-
ported as predefined in themethodology of
the study
Other bias Low risk The study appears to be free of other
sources of bias
Brooks 2004
Methods Randomised, double-blinded, placebo controlled trial conducted in a rural hospital in
Matlab, Bangladesh for 2 years (August 1999 to August 2001) on the effect of zinc
supplementation in addition to standard therapy in children suffering from severe pneu-
monia on time taken to recover and discharge from hospital
Participants Infants (2 to 23 months of age) hospitalised for severe pneumonia i.e. presence of cough,
RR > 50/min, crepitations on chest auscultation and either chest indrawing or lethargy
or inability to feed or cyanosis. Children with concurrent diarrhoea, were receiving zinc
supplements, or who had severe malnutrition were excluded. The participants had low
baseline serum zinc levels. 270 children participated in the trial. The participant popu-
lation lived in economically poor conditions and possibly suffered from malnutrition
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Brooks 2004 (Continued)
Interventions Zinc acetate syrup (10 mg zinc per 5 ml of syrup), 20 mg of elemental zinc was given
daily by mouth in 2 divided doses to the participants until discharge. The control group
received placebo
Outcomes The outcomes reported were mean duration of chest indrawing, RR > 50/min, hypoxia
(oxygen saturation < 95% on air), to cessation of severe pneumonia and discharge from
hospital
Notes Children were treated with intravenous ampicillin + gentamicin
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “We pre allocated group assign-
ments by fixed randomisation using per-
muted
blocks of variable length”
Comment: probably done
Allocation concealment (selection bias) Unclear risk Quote: “A health worker not involved with
the patients care gave all doses”
Comment: no clear method of allocation
concealment stated
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “zinc and placebo syrupswere iden-
tical in appearance, colour, odour, and
taste.” “A health worker not involved with
the patients care gave all doses”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition and exclusion was 2.59%. Rea-
sons for attrition were stated
Selective reporting (reporting bias) Low risk All outcomes have been measured and re-
ported as predefined in themethodology of
the study
Other bias Low risk The study appears to be free of other
sources of bias
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Valentiner-Branth 2010
Methods This study was a double-blind, randomised, placebo-controlled trial in children to mea-
sure the efficacy of daily zinc administration for 14 days on the recovery from severe or
non-severe pneumonia. Trial was conducted in Bhaktapur, Nepal
Participants Children aged 2 to 35 months with severe or non-severe pneumonia according toWHO
definitions and if 6 months had lapsed from a previous enrolment. Non-severe pneu-
monia was defined as fast breathing without LCI. A child had fast breathing if the lower
of 2 counts of RR was 50 breaths/min in children aged 2 to 11 months and 40 breaths/
min in children aged 12 months. Severe pneumonia was defined as LCI but without
general danger signs (i.e. inability to drink/breast feed, persistent vomiting, convulsions,
lethargy or unconsciousness). In a child with wheezing, two 2.5 mg doses of nebulised
salbutamol were given 15 minutes apart, and the child was reassessed after 30 minutes
to establish whether he or she still fulfilled the inclusion criteria.
Exclusion criteria were as follows: non consent, not planning to live in the area for
the next 6 months, requiring special care for very severe disease (i.e. with any general
danger sign), severe malnutrition (defined as being 70% of the median weight for height
according to National Center for Health Statistics standards), presence of congenital
heart disease, documented tuberculosis, documentation of any oral antibiotic treatment
in the past 48 h, cough for 14 d, severe anaemia (defined as haemoglobin, 7 G/dL) or
dysentery
Interventions Zinc 10 mg for children aged 2 to 11 mo and 20 mg for children aged 12 mo
Outcomes For the severe pneumonia stratum, the median time to recovery from severe pneumonia
(i.e. the beginning of a 24 h period without LCI) was 2 d for infants and 1 d for toddlers,
treatment failure, length of hospital stay
Notes The children received antibiotic treatment according to WHO standard case manage-
ment guidelines for pneumonia with oral co-trimoxazole in a dose of 4 mg trimethoprim
/kg bodyweight and 20 mg sulphamethoxazole/kg bodyweight twice daily for 5 d
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomisation was stratified on
age < 1 year and > 1 year as well as on se-
vere and non-severe pneumonia. Children
were allocated to either of the interven-
tion groups by being randomly assigned to
blocks of 16”
Comment: probably done
Allocation concealment (selection bias) Low risk Quote: “For each enrolment, the child was
given a unique serial number and a package
with the intervention or placebo with the
corresponding number”
Comment: probably done
20Zinc supplementation as an adjunct to antibiotics in the treatment of pneumonia in children 2 to 59 months of age (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Valentiner-Branth 2010 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “The randomisation list that linked
the serial numbers to the treatment groups
was generated offsite by using Stata (Stata
Corporation, College Station, TX) by a
scientist who was otherwise not involved
in the study. The scientist sent this list
to the manufacturer of the placebo and
zinc tablets that labelled the packages. The
list was not available for any of those in-
volved in the study until all participants
had been enrolled and completed follow-
up, data cleaning and management were
finished, and the plan of analysis had been
prepared.” “Tablets of both groups were
similar in packaging, appearance, taste, and
inactive ingredients”
Comment: blinding of participants, study
personnel and outcome assessors probably
done
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1300/1314 in the zinc group and 1299/
1314 from the control group
Selective reporting (reporting bias) Low risk Study seems to be free from selective re-
porting
Other bias Low risk Study seems free from other biases
LCI = lower chest indrawing
RR = respiratory rate
h = hours
d = days
mo = months
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Chang 2006 The trial included children up to 11 years of age. They did not report disaggregated data on children of 2 to 59
months of age
Khaled 2001 Published abstract with insufficient information was only available. Also, the outcomes reported by the trial
were not of interest to the review
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(Continued)
Mahalanabis 2002 Trial included children up to 15 years of age with measles accompanied by pneumonia. Both groups received
standard antibiotics along with vitamin A
Mahalanabis 2004 The trial reported sex-based estimates only
Shah 2011 Children were first assigned to zinc and no zinc group and antibiotics were given when they developed acute
ALRI
ALRI = acute lower respiratory infection
Characteristics of ongoing studies [ordered by study ID]
NCT00142285
Trial name or title Zinc pneumonia outpatient trial in children < 2 years
Methods It is a randomised, placebo controlled, double-blind trial to determinewhether zinc canbe used in combination
with standard antibiotics to reduce the duration of illness and the likelihood of treatment failure among
children less than two years old who have non-severe, outpatient pneumonia in an urban slum among children
less than 2 years old
Participants Children up to 23 months with clinical diagnosis of pneumonia. Exclusion will be those with wheezing at
presentation, history of chronic lung, heart or other system disease, suspected tuberculosis, active measles,
severe malnutrition requiring hospitalisation, signs of systemic illness (sepsis, meningitis), those who have
already received zinc/placebo supplements during this study, those known to be pretreated with antibiotics
prior to presenting to clinic
Interventions Oral antibiotics will be given for a standard 5-day course, while zinc (20 mg) or placebo will be administered
once daily for 10 days Patients will be followed up on a daily basis at home to monitor their progress and
document compliance
Outcomes Primary outcome measures: duration of illness, treatment failure
Secondary outcome measures: incidence of subsequent illness episodes (pneumonia and any other)
Starting date November 2004
Contact information Abdullah Brooks, ICDRR, B Centre for health and population research
Notes
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NCT00347386
Trial name or title Zinc as an immunomodulator in the treatment of possible serious bacterial infections in infants 7 days and
up to 4 months of age
Methods This is a double-blind, RCT
Participants Evidence of possible serious bacterial infection, defined as a CRP > 20 mg/L and any one of the following
clinical features
• Fever (axillary temperature > 38 oC) or hypothermia (axillary temperature < 35.5 oC), lethargic or
unconscious, no attachment to the breast in breast fed infants, no suckling in breast fed infants, convulsions
in the present episode, bulging fontanel
• History of acute refusal of feed in the present episode
• Acute history of excessive cry or irritability in the present episode
• Fast breathing defined as > 60 breaths/minute (on second count)
• Grunting in the absence of any non-infective cause
• Cyanosis in the absence of any non-infective cause
• Severe chest indrawing
• Unexplained shock
Exclusion criteria:
• Congenital malformations, e.g. hydrocephalus, structural CNS malformation
• Severe birth asphyxia defined as: One minute APGAR (if available) of < 4/10 CT scan or MRI or EEG
abnormalities if available suggestive of hypoxic ischaemic encephalopathy
• Known structural defects, which interfere with feeding, e.g. cleft palate oesophageal abnormalities,
intestinal atresia and stenosis malrotation of the gut, anorectal malformation
• Subjects requiring ventilation or inotropic support
• History of diarrhea in the present episode
• Known inborn error of metabolism
• Chronic disorders of other organs e.g. neonatal cholestasis, chronic renal failure, pre-existing seizure
disorder
• Infants born of known HIV mothers
• Clinical suspicion of necrotising enterocolitis
• Congenital heart disease
Interventions Drug: zinc (zinc sulphate)
Drug: placebo
Outcomes Primary outcome: proportion with treatment failures
Secondary outcome measures:
the effect of zinc administration on plasma zinc and copper
the efficacy of zinc on the duration of severe bacterial illness
the efficacy of zinc given during severe bacterial illness on markers of inflammation
Starting date March 2005
Contact information Shinjini Bhatnagar, All India Institute of Medical Sciences, New Delhi
Notes
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NCT00373100
Trial name or title Efficacy of zinc as an adjunct therapy in the management of severe pneumonia among Gambian children
Methods RCT from Gambia
Participants Inclusion criteria: children aged 2 to 59 months presenting with severe or very severe pneumonia to the MRC
Hospital or the Royal Victoria Teaching Hospital, Banjul
Exclusion criteria: children with severe malnutrition or signs of systemic infection other than pneumonia
Interventions Zinc sulphate or placebo. Zinc will be given once daily orally at a dose of 10 mg in those aged 2 to 11 months
and 20 mg in those 12 to 59 months. All participants will receive zinc or placebo for 7 days, while a randomly
selected subgroup will receive 6 months supplementation
Please note that this amendment reflects an error in the information provided at time of registration and not
a change in protocol; zinc sulphate has been used throughout the trial
Interventions provided at time of registration: zinc acetate or placebo. Zinc will be given once daily orally at a
dose of 10 mg in those aged 2 to 11 months and 20 mg in those 12 to 59 months. All participants will receive
zinc or placebo for 7 days, while a randomly selected subgroup will receive 6 months supplementation
Outcomes Primary outcome: treatment failure at 5 days
Secondary outcome: the following will be assessed after 6 months supplementation of zinc or placebo in a
subgroup:
1. time to resolution of signs of severe and very severe pneumonia
2. length of admission
3. height
4. multi-antigen skin testing
Starting date 24/10/2005
Contact information showie@mrc.gm
MRC Laboratories, P.O. Box 273, Gambia
Notes
NCT00513929
Trial name or title Zinc as adjunct to treatment of pneumonia (EcuaPAZ)
Methods It is a RCT, double-blind
Participants Inclusion criteria:
children from 2 to 59 months of age with severe pneumonia admitted to the Children’s Hospital, whose
parents are willing to provide written informed consent will be eligible for participation
Exclusion criteria:
children suffering from marasmus or kwashiorkor, measles, pneumonia due to aspiration of a foreign body,
hepatic or renal disease, sepsis, congenital abnormalities (cardiac, renal or genetic), complicated pneumonia
(lung abscess, pleural effusion, pneumatocoele, atelectasis) or severe anaemia (haemoglobin less than 8 g/dL)
children whose parents refuse to provide written informed consent
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NCT00513929 (Continued)
Interventions Dietary supplement: zinc sulphate
Arm X : zinc sulphate 10 mg will be given orally twice a day since admission to resolution of pneumonia
episode in addition to standard antibiotic treatment
Outcomes Primary outcome measures: time (hours) to resolution of clinical signs of pneumonia
Secondary outcome measures: time (hours) to resolution of clinical signs of pneumonia by type of associated
pathogens
Starting date August 2007
Contact information Contact: Fernando E Sempertegui, MD fersempert@andinanet.net
Notes
CRP = C-reactive protein
CNS = central nervous system
APGAR = appearance pulse grimace activity respiration
CT scan = computed axial tomography scan
MRI = magnetic resonance imaging
EEG = electroencephalography
25Zinc supplementation as an adjunct to antibiotics in the treatment of pneumonia in children 2 to 59 months of age (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. Zinc supplementation versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Time-to-clinical recovery 2 2862 Hazard Ratio (Fixed, 95% CI) 1.02 [0.93, 1.11]
1.1 Severe pneumonia 2 408 Hazard Ratio (Fixed, 95% CI) 1.12 [0.89, 1.41]
1.2 Non-severe pneumonia 1 2454 Hazard Ratio (Fixed, 95% CI) 1.0 [0.91, 1.10]
2 Time-to-recovery from
tachypnoea (respiratory rate >
50 breaths per min)
2 Hazard Ratio (Random, 95% CI) Subtotals only
2.1 Severe pneumonia 2 562 Hazard Ratio (Random, 95% CI) 1.13 [0.82, 1.57]
3 TIme-to-recovery from chest
in-drawing
2 Hazard Ratio (Fixed, 95% CI) Subtotals only
3.1 Severe pneumonia 2 562 Hazard Ratio (Fixed, 95% CI) 1.08 [0.88, 1.31]
4 Time-to-hospital discharge 3 Hazard Ratio (Fixed, 95% CI) Subtotals only
4.1 Severe pneumonia 3 707 Hazard Ratio (Fixed, 95% CI) 1.04 [0.89, 1.22]
Analysis 1.1. Comparison 1 Zinc supplementation versus placebo, Outcome 1 Time-to-clinical recovery.
Review: Zinc supplementation as an adjunct to antibiotics in the treatment of pneumonia in children 2 to 59 months of age
Comparison: 1 Zinc supplementation versus placebo
Outcome: 1 Time-to-clinical recovery
Study or subgroup Zinc Placebo log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Severe pneumonia
Brooks 2004 132 131 0.357 (0.172) 6.7 % 1.43 [ 1.02, 2.00 ]
Valentiner-Branth 2010 73 72 -0.0943 (0.1585) 7.9 % 0.91 [ 0.67, 1.24 ]
Subtotal (95% CI) 205 203 14.6 % 1.12 [ 0.89, 1.41 ]
Heterogeneity: Chi2 = 3.72, df = 1 (P = 0.05); I2 =73%
Test for overall effect: Z = 0.97 (P = 0.33)
2 Non-severe pneumonia
Valentiner-Branth 2010 1227 1227 0 (0.0481) 85.4 % 1.00 [ 0.91, 1.10 ]
Subtotal (95% CI) 1227 1227 85.4 % 1.00 [ 0.91, 1.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
0.5 0.7 1 1.5 2
Favours placebo Favours zinc
(Continued . . . )
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(. . . Continued)
Study or subgroup Zinc Placebo log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Total (95% CI) 1432 1430 100.0 % 1.02 [ 0.93, 1.11 ]
Heterogeneity: Chi2 = 4.53, df = 2 (P = 0.10); I2 =56%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Chi2 = 0.80, df = 1 (P = 0.37), I2 =0.0%
0.5 0.7 1 1.5 2
Favours placebo Favours zinc
Analysis 1.2. Comparison 1 Zinc supplementation versus placebo, Outcome 2 Time-to-recovery from
tachypnoea (respiratory rate > 50 breaths per min).
Review: Zinc supplementation as an adjunct to antibiotics in the treatment of pneumonia in children 2 to 59 months of age
Comparison: 1 Zinc supplementation versus placebo
Outcome: 2 Time-to-recovery from tachypnoea (respiratory rate > 50 breaths per min)
Study or subgroup Zinc Placebo log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Severe pneumonia
Bose 2006 150 149 -0.0304 (0.1169) 53.1 % 0.97 [ 0.77, 1.22 ]
Brooks 2004 132 131 0.3008 (0.1434) 46.9 % 1.35 [ 1.02, 1.79 ]
Subtotal (95% CI) 282 280 100.0 % 1.13 [ 0.82, 1.57 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 3.20, df = 1 (P = 0.07); I2 =69%
Test for overall effect: Z = 0.76 (P = 0.45)
0.1 0.2 0.5 1 2 5 10
Favours placebo Favours zinc
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Analysis 1.3. Comparison 1 Zinc supplementation versus placebo, Outcome 3 TIme-to-recovery from chest
in-drawing.
Review: Zinc supplementation as an adjunct to antibiotics in the treatment of pneumonia in children 2 to 59 months of age
Comparison: 1 Zinc supplementation versus placebo
Outcome: 3 TIme-to-recovery from chest in-drawing
Study or subgroup Zinc Placebo log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Severe pneumonia
Bose 2006 150 149 -0.0834 (0.1439) 48.6 % 0.92 [ 0.69, 1.22 ]
Brooks 2004 132 131 0.2231 (0.14) 51.4 % 1.25 [ 0.95, 1.64 ]
Subtotal (95% CI) 282 280 100.0 % 1.08 [ 0.88, 1.31 ]
Heterogeneity: Chi2 = 2.33, df = 1 (P = 0.13); I2 =57%
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours placebo Favours zinc
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Analysis 1.4. Comparison 1 Zinc supplementation versus placebo, Outcome 4 Time-to-hospital discharge.
Review: Zinc supplementation as an adjunct to antibiotics in the treatment of pneumonia in children 2 to 59 months of age
Comparison: 1 Zinc supplementation versus placebo
Outcome: 4 Time-to-hospital discharge
Study or subgroup Zinc Placebo log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Severe pneumonia
Bose 2006 150 149 -0.0726 (0.1171) 47.3 % 0.93 [ 0.74, 1.17 ]
Brooks 2004 132 131 0.2852 (0.1404) 32.9 % 1.33 [ 1.01, 1.75 ]
Valentiner-Branth 2010 73 72 -0.0943 (0.1808) 19.8 % 0.91 [ 0.64, 1.30 ]
Subtotal (95% CI) 355 352 100.0 % 1.04 [ 0.89, 1.22 ]
Heterogeneity: Chi2 = 4.53, df = 2 (P = 0.10); I2 =56%
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours placebo Favours zinc
A D D I T I O N A L T A B L E S
Table 1. Zinc supplementation versus placebo
Study Supplementation Schedule Antibiotic Definition of clini-
cal recovery
Discharge criteria
Zinc Placebo
Bansal 2011 Zinc gluconate
20 mg
Placebo Daily Parenteral antibiotic Time to be asymp-
tomatic was defined
as resolution of all
four of the following
symptoms: 1) danger
signs; 2) respiratory
distress; 3) tachyp-
noea and 4) hypoxia
in room air, for at
least 24 h
Children were dis-
charged from hospi-
tal when they were
asymptomatic for at
least 24 h
Bose 2006 Zinc sulphate
20 mg
Placebo Daily Inj. benzyl penicillin
+ gentamicin
Resolution of the fol-
lowing: 1) respiratory
rate 50 breaths/min
and oxygen satura-
tion 93%; 2) inabil-
Children were dis-
charged when they
were being fed en-
tirely with oral feeds,
the respiratory rate
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Table 1. Zinc supplementation versus placebo (Continued)
ity to drink, respira-
tory rate 50 breaths/
min, and oxygen sat-
uration 93%; and
3) chest indrawing,
respiratory rate 50
breaths/min and oxy-
gen saturation 93%
for at least 16 h
was 50 breaths/min,
oxygen saturation
was 93%, and the at-
tending paediatrician
decided that the pa-
tient’s clinical condi-
tion had resolved and
did not require fur-
ther hospital care
Brooks 2004 Zinc acetate
20 mg
Placebo Daily Inj. ampicillin + gen-
tamicin
Resolution of the fol-
lowing: 1) chest in-
drawing; 2) respira-
tory rate more than
50 per min; and 3)
hypoxia (oxygen sat-
uration <95%) for at
least 24 h
Children were dis-
charged from hospi-
tal once respiratory
rate fell to less than
or equal to 40 breaths
per min for 24 con-
secutive h, with no
recurrence of respira-
tory distress,
other danger signs, or
fever (temperature >
37·9°C)
Valentiner-
Branth 2010
Zinc sulphate
10 mg for < 12
months
and 20 mg for >
12 months
Placebo Twice daily Oral co-trimoxazole
for non-severe pneu-
monia
benzyl penicillin for
severe pneumonia
Recovery was defined
as the
beginning of the first
24 h period without
LCI, without grunt-
ing and with no nasal
flaring for at least 24
h
The child was con-
sidered for discharge
when he/she
recovered from severe
pneumonia
LCI = lower chest indrawing; h= hour
Table 2. Median recovery time
Study Outcome Zinc group Placebo group
Bansal 2011 Median (IQR) Time to be asymptomatic (h) 60 (24, 78) 54 (30, 72)
Time to resolution of respira-
tory distress (h)
30.5 (16, 48) 24 (13, 48)
Time to resolution of tachyp-
noea (h)
60 (24, 72) 48 (24, 72)
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Table 2. Median recovery time (Continued)
Time to disappearance of dan-
ger signs (h)
20 (8, 36) 16 (8, 30)
Valentiner-Branth 2010 Me-
dian (IQR)
Time to recovery from severe
pneumonia (d)
2 (1, 3) 2 (1, 3)
Time to recovery (d) 4 (2, 7) 3 (2, 6)
Time to discharge fromhospital
(d)
3 (3, 4) 3 (3, 4)
Bose 2006 Median (95% CI) Time to be asymptomatic (h)
(Inability to feed,O2 saturation
< 93%, RR > 50)
(Chest indrawing, O2 satura-
tion <93%, RR > 50)
(O2 saturation <93%,RR>50)
87.2 (70.7, 95.2)
111.3 (88.5, 138.0)
82.2 (70.3, 92.2)
76.2 (72.3, 88.1)
96.7 (78.2, 112.9)
75.9 (71.2, 88.0)
Time to resolution of tachyp-
noea (RR > 50) (h)
72.0 (68.5, 88.0) 73.0 (64.5, 82.8)
Hospitalisation (h) 71.1 (68.1, 87.3) 72.3 (67.7, 79.6)
Brooks 2004 Median (95% CI) Time to recovery from severe
pneumonia (h)
72 (72, 96) 96 (72, 96)
Chest indrawing 40 (39, 48) 48 (40, 56)
Hospital stay (d) 112 (104, 112) 112 (111, 129)
IQR= interquartile range; h = hour; d = day; CI = confidence interval; RR = respiratory rate
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
MEDLINE (Ovid)
1 exp Pneumonia/
2 pneumon*.tw.
3 lower respiratory tract infection*.tw.
4 lower respiratory infection*.tw.
5 LRTI.tw.
6 or/1-5
7 Zinc/
8 zinc.tw.
9 or/7-8
10 exp Child/
11 child*.tw.
12 exp Infant/
13 infant*.tw.
14 (paediatric* or pediatric* or toddler* or preschool*).tw.
15 or/10-14
16 6 and 9 and 15
Appendix 2. CENTRAL search strategy
#1MeSH descriptor Pneumonia explode all trees
#2(pneumon*):ti,ab,kw
#3(lower respiratory tract infection*):ti,ab,kw
#4(lower respiratory infection*):ti,ab,kw
#5(lrti):ti,ab,kw
#6(#1 OR #2 OR #3 OR #4 OR #5)
#7MeSH descriptor Zinc explode all trees
#8(zinc):ti,ab,kw
#9(#7 OR #8)
#10(#6 AND #9)
Appendix 3. EMBASE search strategy
Embase.com
#14. #5 AND #8 AND #13
#13. #9 OR #10 OR #11 OR #12
#12. pediatric*:ab,ti OR paediatric*:ab,ti OR toddler*:ab,ti OR preschool*:ab,ti
#11. ’pediatrics’/exp
#10. child*:ab,ti OR infant*:ab,ti OR infancy:ab,ti
#9. ’child’/exp
#8. #6 OR #7
#7. zinc:ab,ti
#6. ’zinc’/exp
#5. #1 OR #2 OR #3 OR #4
#4. ’lower respiratory tract infection’:ab,ti OR ’lower respiratory tract infections’:ab,ti OR ’lower respiratory infection’:ab,ti OR ’lower
respiratory infections’:ab,ti OR lrti:ab,ti
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#3. ’lower respiratory tract infection’/de
#2. pneumon*:ab,ti
#1. ’pneumonia’/exp
Appendix 4. CINAHL search strategy
CINAHL (Ebsco)
S10 S6 and S9
S9 S7 or S8
S8 TI zinc or AB zinc
S7 (MH “Zinc”)
S6 S1 or S2 or S3 or S4 or S5
S5 TI lrti or AB lrti
S4 TI lower respiratory tract infection* or AB lower respiratory tract infection*
S3 TI lower respiratory infection* or AB lower respiratory infection*
S2 TI pneumon* or AB pneumon*
S1 (MH “Pneumonia+”)
Appendix 5. LILACS search strategy
Database : LILACS
Search on : Mh Pneumonia OR Tw pneumon$ OR Tw neumon$ [Words] and Mh Zinc OR Tw zinc$ [Words]
Appendix 6. AMED search strategy
AMED (Ovid)
1 pneumonia/
2 pneumon*.tw.
3 lower respiratory tract infection*.tw.
4 lower respiratory infection*.tw.
5 lrti.tw.
6 or/1-5
7 zinc/
8 zinc.tw.
9 7 or 8
10 6 and 9
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Appendix 7. CAB Abstracts search strategy
CAB Abstracts (Thomson Reuters)
Topic=(pneumon* or lower respiratory tract infect* or lower respiratory infect*) AND Topic=(zinc)
Timespan=2010. Databases=CAB Abstracts.
Appendix 8. Web of Science search strategy
Web of Science (Thomson Reuters)
Topic=(pneumon* or lower respiratory tract infect* or lower respiratory infect*) AND Topic=(zinc)
Refined by: Topic=(child* or infant* or toddler* or preschool* or pediatric* or paediatric*)
Timespan=2010. Databases=SCI-EXPANDED, CPCI-S.
WH A T ’ S N E W
Date Event Description
17 January 2013 Amended Measurement of treatment effect section: Methods for the analysis of time-to-event outcome added.
Types of outcome measures: clearly listed as time-to-event outcomes
C O N T R I B U T I O N S O F A U T H O R S
Batool A Haider (BAH) and Zohra S Lassi (ZSL) extracted, entered and analysed the data and wrote the text of the review. Amina
Ahmed also contributed to data extraction. Zulfiqar A Bhutta (ZAB) provided support and guidance for the review.
D E C L A R A T I O N S O F I N T E R E S T
ZAB has been involved in a study of zinc supplementation for the treatment of diarrhoea in children. BAH and ZAB have also
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